Optimized Solid Tumor Next-Generation Sequencing (NGS) Panel: Clinical Impact of Unique Informative Content Beyond Commercial Assays

AMP 2025

Nov 11, 2025
Oncology
Abstract

A. Khanshour, M. Awobajo-Otesanya, M. Bhandari, C. Tang, Z. Wang, E. Ostman, H. Zheng, H. Yao, L. Li, M. Cantu, J. Xu, J. Park, J. SoRelle

Introduction
Comprehensive genomic profiling is critical in the

 

management of solid tumors, yet next-generation sequencing (NGS)

 

panel size does not always correlate with clinical utility. We evaluated the

 

performance of our in-house solid tumor NGS panel to identify

 

opportunities for strategic refinement and to compare its utility against

 

leading commercial assays. Methods: We conducted a retrospective

 

analysis of 2,085 solid tumor cases reported by the UT Southwestern

 

(UTSW) Clinical NGS Laboratory between December 2018 and April

 

  1. All cases were analyzed using our customized solid tumor NGS

 

panel targeting 1,516 genes. Standard bioinformatics pipelines and quality

 

control measures were applied. Genes were categorized based on their

 

reporting frequency and clinical informativeness, defined by the presence

 

of Tier I/II variants. The UTSW panel was benchmarked against 3

 

commercial assays – Illumina TSO500 (523 genes), Tempus xT (649

 

genes), and SOPHiA GENETICS Cancer Profiling Solution panel (480

 

genes) – to identify unique, shared, and underrepresented genes.

 

Results
A total of 308 genes of the UTSW panel were classified as

 

clinically informative, forming a strong foundation for streamlined testing

 

and potential panel optimization. Among them, 58 genes (19%) were

 

uniquely informative – absent from all 3 commercial assays. Of these, 20

 

genes are listed in the Cancer Gene Census in COSMIC database as

 

somatic cancer-associated genes. Notably, 12 of the 58 unique genes

 

(AFF3, AUTS2, BAZ2A, CAMTA1, CD44, DGKB, GTF2I, PRKCA, RGS7,

 

RPL22, RUNX2, and WHSC1) have well-established oncologic

 

associations, with Tier I/II variants identified in 10 internal cases. These

 

variants contributed additional diagnostic and/or prognostic value,

 

underscoring the relevance of these genes for the tumor types routinely

 

tested at the UTSW Clinical NGS Laboratory. Conclusions: Our study

 

demonstrates that the UTSW customized NGS solid tumor panel provides

 

substantial clinical value beyond what is captured by leading commercial

 

assays. The identification of 58 uniquely informative genes – many with

 

established oncologic relevance and documented Tier I/II variants –

 

highlights the importance of context-specific panel design. These findings

 

support the strategic refinement of genomic testing to prioritize clinically

 

actionable content, ultimately enhancing diagnostic precision and

 

personalized cancer care.